Collaboration Promises Better, More Accurate Breast Cancer Diagnostics

In In The News by Barbara Jacoby

From: PR Newswire

Data-sharing result s in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results.

The Health Exchange Market, or T.H.E.M.™, together with LabCorp, Konica Minolta, Inc. University of Rochester, Penn State Hershey Medical Center and Lebanon VA Medical Center, has presented significant findings in breast cancer research at the 2018 San Antonio Breast Cancer Symposium®. The study (Number 851014) is titled: ASCO/CAP human epidermal growth factor receptor-2 (HER2) in situ hybridization (ISH) categories evaluated by quantitative HER2 protein diagnostic methodologies: A comparative analysis.

Each year, over 20,000+ women with HER2 Positive Breast Cancer in the US are in danger of being misdiagnosed and subsequently mistreated. T.H.E.M. identified the research project needs and appropriate study members, and helped facilitate the analysis using new and historical companion data. The effort was successful in improving the diagnostic accuracy by 20% in stage 3 and stage 4 patients. The project was completed in under four months, thanks to the cooperation of all study members.

“We are pleased to help facilitate such an impactful study and remain more optimistic than ever that the healthcare community can accomplish great transformations through sharing data that would otherwise be impossible alone.” says T.H.E.M.™, Founder and CEO, Collin Powell. “We want to thank everyone for their participation in this collaborative effort, as well as the The San Antonio Breast Cancer Symposium® for helping us raise awareness and secure adoption. We are hopeful these findings will aid with ongoing research efforts aimed at breast cancer prevention and maintenance, and eventually lead to the eradication of this aggressive disease altogether.”

ABOUT: T.H.E.M.™ is a global bio-bank for de-identified healthcare data, providing a marketplace that allows health data owners to create new and ongoing revenue streams from existing data, and provides buyers with a smarter, cost effective solution to obtaining data from various sources.

ABOUT: LabCorp, an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. LabCorp reported net revenues of over $10 billion in 2017.

ABOUT: Konica Minolta Inc, Bio Health Care Business Development Division, Corporate R&D Headquarter, No. 1 Sakura-machi, Hino-shi Tokyo 191-8511, Japan. Konica Minolta reported net revenues of over $15.8 Billion in 2017.